Security
Eloxx Pharmaceuticals, Inc. Common Stock · ELOX
ELOXOTCCommon stockHistorical · closed Jun 1, 2026CIK 1035354Updated Oct 23, 2026
Name history
Sevion Therapeutics, Inc. · through Dec 22, 2017SENESCO TECHNOLOGIES INC · through Sep 29, 2014NAVA LEISURE USA INC · through May 24, 1999
Current security for this SEC filerELOX · NASDAQ
ELOX price & chart
Historical security
This listing closed Jun 1, 2026. Live provider charts are shown only for current listings.
Current security: ELOX
About the company
We are a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (“NMs”) to enable the production of full-length proteins. Targeting ribosome subunits provides a therapeutic approach to addressing a number of genetic diseases. According to the Human Gene Mutation Database, NMs account for approximately 10% to 12% of patients with a given genetic disease. There are over 7,000 inherited genetic diseases that collectively affect 350 million people worldwide. Our immediate focus is to advance the clinical development of our product candidate, exaluren, for the treatment of rare kidney diseases. We have also exclusively licensed our product candidate, ZKN-013, to Almirall, S.A. (“Almirall”), who is developing it for the treatment of rare skin diseases.
In the news
No coverage from other publishers is available.
Recent filings
424B3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
EFFECT filing
S-1 filing
SCHEDULE 13G - filed by Samsara BioCapital, L.P. regarding Eloxx Pharmaceuticals, Inc.
Show 5 more recent filings
SCHEDULE 13G - filed by Nantahala Capital Management, LLC regarding Eloxx Pharmaceuticals, Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G - filed by Aberdeen Group plc regarding Eloxx Pharmaceuticals, Inc.
SCHEDULE 13G - filed by Coastlands Capital LP regarding Eloxx Pharmaceuticals, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2023 | Q3 2022 | Q2 2026 | Q2 2025 | Q2 2023 | Q1 2026 | Q1 2025 | Q1 2023 | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,042,000Source | 26,879,000Source | 63,388,000Source | — | 5,993,000Source | 8,503,000Source | — | 7,200,000Source | 5,270,000Source | 2,976,000Source | 21,123,000Source | 45,139,000Source |
| Property, Plant and Equipment, NetUSD | 107,000Source | 215,000Source | — | — | 130,000Source | — | — | 143,000Source | 0Source | 0Source | 169,000Source | 216,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,775,000Source | 24,554,000Source | 61,960,000Source | 572,000Source | 4,331,000Source | 6,363,000Source | 450,000Source | 4,904,000Source | 4,785,000Source | 111,000Source | 19,207,000Source | 42,268,000Source |
| Assets, CurrentUSD | 5,629,000Source | 25,671,000Source | 63,388,000Source | — | 5,382,000Source | 8,503,000Source | — | 6,403,000Source | 5,270,000Source | 2,976,000Source | 20,129,000Source | 43,480,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 635,000Source | 854,000Source | 1,422,000Source | — | 841,000Source | 2,134,000Source | — | 1,238,000Source | 479,000Source | 142,000Source | 661,000Source | 913,000Source |
| Operating Lease, Right-of-Use AssetUSD | 306,000Source | 993,000Source | — | — | 481,000Source | — | — | 654,000Source | 0Source | 0Source | 825,000Source | 1,443,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 26,090,000Source | 31,861,000Source | — | — | 24,589,000Source | — | — | 23,493,000Source | 17,177,000Source | 27,311,000Source | 31,783,000Source | 22,755,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 31,000Source | 871,000Source | 40,000Source | — | 25,000Source | 51,000Source | — | 22,000Source | 48,000Source | 35,000Source | 22,000Source | 871,000Source |
| Retained Earnings (Accumulated Deficit)USD | -288,551,000Source | -268,069,000Source | -308,836,000Source | — | -284,959,000Source | -304,334,000Source | — | -280,618,000Source | -300,580,000Source | -294,585,000Source | -274,388,000Source | -238,323,000Source |
| Stockholders' Equity Attributable to ParentUSD | -20,048,000Source | -4,982,000Source | 46,420,000Source | -27,899,000Source | -18,596,000Source | -7,584,000Source | -26,024,000Source | -16,293,000Source | -11,907,000Source | -24,335,000Source | -10,660,000Source | 22,384,000Source |
| Additional Paid in Capital, Common StockUSD | 268,472,000Source | 264,406,000Source | 355,216,000Source | — | 266,379,000Source | 296,699,000Source | — | 264,303,000Source | 288,625,000Source | 270,215,000Source | 263,706,000Source | 262,026,000Source |
| Liabilities and EquityUSD | 6,042,000Source | 26,879,000Source | 63,388,000Source | — | 5,993,000Source | 8,503,000Source | — | 7,200,000Source | 5,270,000Source | 2,976,000Source | 21,123,000Source | 45,139,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 23,466,000Source | 21,680,000Source | 16,968,000Source | — | 21,251,000Source | 16,087,000Source | — | 19,460,000Source | 17,177,000Source | 27,311,000Source | 23,091,000Source | 9,955,000Source |
| Operating Lease, Liability, CurrentUSD | 315,000Source | 698,000Source | — | — | 492,000Source | — | — | 667,000Source | 0Source | 4,000Source | 712,000Source | 657,000Source |
| Accounts Payable, CurrentUSD | 3,134,000Source | 1,595,000Source | 3,028,000Source | — | 3,121,000Source | 3,028,000Source | — | 2,434,000Source | 2,713,000Source | 5,346,000Source | 3,020,000Source | 1,379,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,000Source | 318,000Source | — | — | 4,000Source | — | — | 6,000Source | 0Source | 0Source | 135,000Source | 804,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,442,000Source | 4,518,000Source | 2,047,000Source | — | 2,752,000Source | 1,236,000Source | — | 2,230,000Source | 1,613,000Source | 1,446,000Source | 2,799,000Source | 4,196,000Source |
| Long-term Debt, Current MaturitiesUSD | 2,819,000Source | 2,530,000Source | 0Source | — | 2,276,000Source | 0Source | — | 1,536,000Source | 1,000,000Source | 6,516,000Source | 3,980,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 2,621,000Source | 9,863,000Source | — | — | 3,334,000Source | — | — | 4,027,000Source | 0Source | 0Source | 8,557,000Source | 11,996,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | — | — | —Source | — | — | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q3 2023 | Q3 2022 | Q2 2026 | Q2 2025 | Q2 2023 | Q1 2026 | Q1 2025 | Q1 2023 | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | -3,754,000Source | -1,709,000Source | -6,230,000Source | -5,995,000Source | -3,143,000Source | -36,065,000Source | -66,727,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 46,000Source | 20,000Source | 597,000Source | 235,000Source | 541,000Source | 3,021,000Source | 9,167,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | -359,000Source | 359,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | 315,000Source | -139,000Source | -586,000Source | -2,633,000Source | -353,000Source | 1,641,000Source | -320,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -5,453,000Source | 1,204,000Source | -6,814,000Source | -6,327,000Source | -4,715,000Source | -31,845,000Source | -35,001,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 11,000Source | 1,000Source | 38,000Source | -66,000Source | 2,056,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | — | — | 66,000Source | 89,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 362,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | 7,031,000Source | -865,000Source | -7,500,000Source | 11,001,000Source | 3,439,000Source | 8,812,000Source | 50,788,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | 1,578,000Source | 339,000Source | -14,303,000Source | 4,675,000Source | -1,238,000Source | -23,099,000Source | 17,843,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | 0Source | 40,000Source | 430,000Source | 25,000Source | 139,000Source | 1,365,000Source | 728,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | 418,000Source | 714,000Source | 95,000Source | 16,000Source | 610Source | 46,000Source | 20,000Source | 597,000Source | 235,000Source | 541,000Source | 3,021,000Source | 9,167,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | 15,000Source | 0Source | 35,000Source | 77,000Source | 114,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -3,000Source | -35,000Source | — | — | -19,000Source | — | — | -11,000Source | — | — | -3,000Source | 2,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 1,000Source | 38,000Source | 0Source | -84,000Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | -255,000Source | 0Source | — | — | — | — | — | — | -1,000Source | -38,000Source | — | — |
| General and Administrative ExpenseUSD | 2,387,000Source | 2,262,000Source | 1,610,000Source | 684,000Source | 1,802,000Source | 2,136,000Source | 712,000Source | 1,995,000Source | 3,382,000Source | 5,250,000Source | 10,692,000Source | 20,449,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 36,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -3,592,000Source | -7,508,000Source | -4,502,000Source | -1,891,000Source | -4,341,000Source | -3,754,000Source | -1,709,000Source | -6,230,000Source | -5,995,000Source | -3,143,000Source | -36,065,000Source | -66,727,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 27,000Source | -53,000Source | — | — |
| Operating ExpensesUSD | 3,637,000Source | 7,142,000Source | 4,450,000Source | 1,582,000Source | 4,140,000Source | 3,795,000Source | 1,222,000Source | 5,483,000Source | 6,438,000Source | 8,827,000Source | 34,419,000Source | 66,018,000Source |
| Other Nonoperating Income (Expense)USD | 45,000Source | -366,000Source | -52,000Source | -309,000Source | -201,000Source | 41,000Source | -487,000Source | -747,000Source | 443,000Source | -675,000Source | -1,646,000Source | -709,000Source |
| Proceeds from Issuance of Common StockUSD | 1,722,000Source | — | — | — | 1,428,000Source | — | — | — | 0Source | 0Source | 0Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | 0Source | 390,000Source | — | 2,865,000Source | 3,668,000Source | 0Source | 11,874,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | 40,000Source | 0Source | — | — | — | 0Source | 23,000Source |
| Gain (Loss) on Extinguishment of Debt | — | —Source | —Source | —Source | — | —Source | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2017 | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 | Q1 2018 | FY 2025 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 6,359,000Source | — | — |
| Operating Income (Loss)USD | — | — | — | — | — | — | — | -627,449Source | -2,468,000Source | -34,419,000Source | -66,018,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -675,000Source | -1,646,000Source | -709,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | -1,266,978Source | -3,143,000Source | -36,065,000Source | -66,727,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | -6,230,000Source | -11,620,000Source | -8,694,000Source | -13,946,000Source | -11,917,000Source | -8,591,000Source | -1,266,978Source | -3,143,000Source | -36,065,000Source | -66,727,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | — | — | — | — | -0.84Source | -16.65Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | -0.84Source | -16.65Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | — | — | — | — | 3,758,804Source | 2,166,311Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | 3,758,804Source | 2,166,311Source | — |
| Additional Financial Items | |||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | -3,000Source | 2,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | 3,393,000Source | 491,810Source | 5,250,000Source | 10,692,000Source | 20,449,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 36,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 637,000Source | -22,991,000Source | -47,849,000Source |
| Interest and Other IncomeUSD | — | — | — | — | — | — | — | — | 27,000Source | 274,000Source | 8,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -53,000Source | — | — |
| Operating ExpensesUSD | — | — | — | — | — | — | 8,548,000Source | — | 8,827,000Source | 34,419,000Source | 66,018,000Source |
| Costs and Expenses | — | — | — | — | — | — | — | —Source | — | — | — |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | — | — | — | — | — | —Source | — | — | — |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | —Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | —Source | — | — | — |
| Preferred Stock Dividends, Income Statement Impact | — | — | — | — | — | — | — | —Source | — | — | — |
| Research and Development Expense | — | — | — | — | — | — | —Source | —Source | — | — | — |
Offerings
Registration 333-298904
Registration 333-295651
- Gross proceeds
- 65969750.0
- Net proceeds
- 61349750.0
- Deal price
- 11.0
- Shares
- 5997250
- Offering price
- $11.00
- Ticker
- ELOX
Underwriters: Leerink Partners LLC, Guggenheim Securities, LLC
Filing attachments
d167833dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d167833dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company’s balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 ──────────────────────────────…
Read attachment ↗tm2618241d1_ex99-1.htm · SCHEDULE 13G · 2026-06-17
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersign…
Read attachment ↗ex991.htm · SCHEDULE 13G · 2026-06-16
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigne…
Read attachment ↗tm2613376d1_ex99-1.htm · SCHEDULE 13G · 2026-05-01
EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersign…
Read attachment ↗